Genomic Vision: share price rises, financial visibility welcomed
As of March 31, the biotech company specialized in the analysis of genome modifications had a cash position of 43,000 euros, compared with 760,000 euros a year earlier.
However, the company also points out that it has a net balance of 23.96 million euros from a 15-tranche OCABSA financing line concluded last year with Winance.
In the first quarter, revenues were up 12% to 435,000 euros, with sales up 13% to 312,000 euros.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction